Pipeline/Assets

Our pipelines consist of commercial launches of several biosimilar drugs targeting blockbuster indications in therapeutic areas of diabetes, obesity, and beyond.

Bioequivalent/Biosimilar Pipeline

Liraglutide (Victoza®) Octreotide (Sandostatin®) Eteplirsen (Exondys 51®) Corticotropin (Acthar Gel®) Lanreotide (Somatuline Depot®) Semaglutide (Wegovy®) Semaglutide (Rybelsus®) Semaglutide (Ozempic®) Teduglutide (Gattex®) Liraglutide (Saxenda®) Teriparatide (Forteo®) RNA therapy Somatostatin ACTH GLP-2 GLP-1 pTH Short Bowel Syndrome DMD Obesity Type 2 Diabetes Osteoporosis Forteo® is a registered trademark of Eli Lilly and Company, its subsidiaries, or affiliates. Victoza®, Saxenda®, Rybelsus®, Wegovy®, and Ozempic® are registered trademarks of Novo Nordisk A/S. Gattex® is a registered trademark of Takeda Pharmaceuticals, U.S.A,. Inc. Somatuline® Depot is a registered trademark of Ipsen Biopharmaceuticals, Inc. Acthar Gel® is a registered trademark of is a Mallinckrodt Pharmaceuticals. Exondys 51® is a registered trademark of Sarepta Therapeutics, Inc. Sandostatin® is a registered trademark of Novartis Pharmaceuticals Corporation.